Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

this-performance-food-group-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-tue

This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tue

Jul 7, 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
analysts-bullish-on-apotex-as-they-initiate-coverage-following-canadian-drugmaker’s-ipo

Analysts bullish on Apotex as they initiate coverage following Canadian drugmaker’s IPO

Jul 7, 2026

Empty pill bottles are filled with Apo-Clonidine, an antihypertensive or vascular stabilizer, at the Apotex Health Corp. plant…

Read more
morgan-stanley-analyst-initiates-spacex-coverage,-sees-nearly-90%-upside-for-elon-musk’s-spcx

Morgan Stanley Analyst Initiates SpaceX Coverage, Sees Nearly 90% Upside for Elon Musk’s SPCX

Jul 7, 2026

Adam Jonas Bullish on SpaceX In a new note released on Monday, Jonas predicted a bull case of…

Read more
abivax-sa-(abvx)-uc-opportunity:-oral-therapy-catalyst

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst

Jul 7, 2026

Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late…

Read more
french-clinical-stage-biotech’s-uc-drug-faces-‘best-in-disease’-doubts-as-analyst-lifts-target-ahead-of-4q26-fda-filing

French Clinical-Stage Biotech’s UC Drug Faces ‘Best in Disease’ Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing

Jul 7, 2026

A Wedbush analyst raised its target on a French biopharma’s ulcerative colitis candidate but disputed bullish efficacy claims,…

Read more
gartner-and-forrester-in-the-age-of-ai-search:-do-analyst-rankings-still-matter?

Gartner and Forrester in the Age of AI Search: Do Analyst Rankings Still Matter?

Jul 7, 2026

This may take a few seconds.

Read more
how-do-analysts-rate-this-biotech-focused-on-chronic-inflammatory-diseases?

How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?

Jul 7, 2026

Find out what analysts think of clinical-stage biotech Abivax SA (ABVX:NASDAQ), which is focusing on harnessing the immune…

Read more

Intention to Cease Coverage of Myer

Jul 6, 2026

We intend to drop coverage of Myer on or around Aug. 6, 2026. We provide analyst research and…

Read more
fulton-financial-(fult)-could-be-45%-undervalued-after-fresh-analyst-coverage

Fulton Financial (FULT) Could Be 45% Undervalued After Fresh Analyst Coverage

Jul 6, 2026

Index removal and fresh coverage bring Fulton Financial into focus Fulton Financial (FULT) has come into focus after…

Read more
here-are-monday’s-best-wall-street-analyst-research-calls:-agnico-eagle-mines,-datadog,-delta-air-lines,-gilead-sciences,-okta,-pfizer,-regions-financial,-t-mobile,-and-more

Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

Jul 6, 2026

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of…

Read more
this-parabilis-medicines-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-monday

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Jul 6, 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
keybanc-initiates-waystar-holding-stock-coverage-with-overweight-rating

KeyBanc initiates Waystar Holding stock coverage with overweight rating

Jul 5, 2026

KeyBanc initiates Waystar Holding stock coverage with overweight rating

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 10
  6. 11
  7. 12
  8. 13
  9. 14
  10. 15
  11. 16
  12. ...
  13. 452
  14. »

Posts pagination

Newer posts Page 1 … Page 13 … Page 452 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.